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1. ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease and one of the major 
causes of death among cancer patients. Diagnosis of PDAC during the early 
stages of cancer is difficult because no effective screening for detection of early 
stage tumors is yet available. PDAC is sustained by a distinct subset of quiescent 
cells, called cancer stem cells (CSCs) that are responsible for resistance to 
standard therapy, metastatic potential and disease relapse following treatments. 
The current therapy for PDAC preferentially targets the more differentiated cancer 
cell population, leaving CSCs as a source that supports the tumour, causing 
recurrence. For this reason, targeting pancreatic CSCs could contribute to the 
clinical development of more efficacious drugs treatment, aimed to permanently 
remove the tumor and prevent recurrence. In this study, we investigated two 
therapeutic approaches for the treatment of PDAC. First of all, we studied a pro-
drug approach using gemcitabine conjugated with fatty acid chains, C12 GEM 
and C18 GEM, by testing their cytotoxic activity on Panc1 cell line and the 
derived CSCs. Both cell lines were more sensitive to the treatment with the 
lipophilic pro-drugs than GEM, but only Panc1 CSCs showed a high sensitivity to 
C18 GEM treatment. Furthermore, the two cell lines exhibited different 
intracellular uptake mechanisms of the drugs that involved mainly membrane 
nucleoside transporters in Panc1 parental cells or fatty acid translocase CD36 for 
C18 GEM uptake in both cell lines. Furthermore, we have highlighted a peculiar 
feature of CSCs regarding the apoptotic response to treatment. In Panc1 parental 
cells, the treatments induced a PARP-dependent apoptosis, while in Panc1 CSCs 
they involved a mechanism of caspase-independent apoptosis mediated by AIF. 
The second therapeutic approach concerned a targeted drug delivery system using 
PEGylated liposomes containing disulfiram (DSF) or diethyldithiocarbamate-
copper (Cu(DDC)2) and liposomes selective for pancreatic CSCs expressing 
CD44 coated with HA. We evaluated the effect on cell proliferation of the various 
DSF formulations using pancreatic CSCs derived from cell lines or patients. The 
encapsulation of Cu(DDC)2 complex in liposomes increased its anti-proliferative 
activity on our cell models. This method represents a good strategy to make the 
Cu(DDC)2 complexes suitable for PDAC patients. In this study, we propose two 
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valid and alternative therapeutic approaches with a promising potential to achieve 
efficient and encouraging results in PDAC treatment.  
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2. SOMMARIO 
L’adenocarcinoma pancreatico duttale (PDAC) è una malattia letale e rappresenta 
una delle principali cause di morte per cancro. La diagnosi precoce del tumore è 
difficile perché screening efficaci che lo diagnostichino nei primi stadi non sono 
ancora disponibili. Il PDAC è sostenuto da una sottopopolazione di cellule 
quiescenti, chiamate cellule staminali tumorali (CSCs) che sono responsabili della 
resistenza alle terapie convenzionali, delle metastasi e delle recidive in seguito ai 
trattamenti. L’attuale terapia per il trattamento del PDAC colpisce 
preferenzialmente la popolazione di cellule tumorali più differenziate, lasciando le 
CSCs come sorgente che supporta lo sviluppo del tumore, causando recidive della 
malattia. Per questo motivo, è importante scoprire nuovi trattamenti più efficaci e 
specifici per le cellule staminali tumorali pancreatiche, che rimuovano 
definitivamente il tumore e prevengano le recidive. In questo lavoro abbiamo 
studiato due approcci terapeutici per il trattamento del PDAC. Il primo approccio 
è stato quello delle pro-drugs, nel quale abbiamo utilizzato la gemcitabina (GEM) 
coniugata con catene di acidi grassi di diversa lunghezza, C12 GEM e C18 GEM. 
La loro attività citotossica è stata saggiata sulla linea cellulare Panc1 e sulle CSCs 
derivate da questa linea. Entrambe le linee cellulari sono risultate più sensibili al 
trattamento con le pro-drugs lipofile rispetto alla GEM, ma solo le CSCs hanno 
mostrato una forte sensibilità alla C18 GEM. Inoltre, le due linee cellulari hanno 
mostrato possedere differenti meccanismi di uptake intracellulari per le droghe, 
che implicano principalmente i trasportatori nucleosidici di membrana nelle Panc1 
parentali, o la trasclocasi degli acidi grassi CD36 per la C18 GEM in entrambe le 
linee cellulari. Inoltre, abbiamo evidenziato una caratteristica peculiare delle 
CSCs che riguarda la risposta apoptotica al trattamento. Nelle Panc1 parentali, i 
trattamenti inducono un’apoptosi PARP-dipendente, mentre nelle Panc1 CSCs 
viene innescato un meccanismo di apoptosi caspasi-indipendente mediato da AIF. 
Il secondo approccio studiato riguarda un sistema specifico di somministrazione 
delle droghe che fa uso dei liposomi decorati con PEG e contenenti disulfiram 
(DSF) o dietilditiocarbammato-rame (Cu(DDC)2), e liposomi selettivi per CSCs 
pancreatiche esprimenti CD44 decorati con acido ialuronico. Abbiamo valutato, 
quindi, l’effetto delle varie formulazioni di DSF sulla proliferazione cellulare di 
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CSCs pancreatiche derivate da linee cellulari o da pazienti. L’incapsulamento del 
complesso Cu(DDC)2 nei liposomi aumenta la sua attività anti-proliferativa nei 
nostri modelli cellulari. Questo metodo rappresenta una buona strategia per 
rendere i complessi Cu(DDC)2 adatti per la somministrazione ai pazienti. In 
questo studio noi proponiamo due validi ed alternativi approcci terapeutici con un 
promettente potenziale per raggiungere risultati efficaci ed incoraggianti nel 
trattamento del PDAC.  
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3. INTRODUCTION 
Pancreatic cancer is caused by the abnormal and uncontrolled growth of cells in 
the pancreas, a large gland in the digestive and endocrine systems. There are 
different types of pancreatic cancer divided into two main groups: exocrine 
tumours that start in the exocrine cells, where enzymes which help food digestion 
are made; endocrine tumours, also called neuroendocrine tumours, that start in the 
endocrine cells, which produce and release insulin and other hormones (Fig.1). 
Most pancreatic cancers are exocrine and more than 8 out of 10 are ductal 
adenocarcinomas (1).  
 
Fig.1: Anatomical representation of the pancreas consisting of an endocrine and an 
exocrine part. Endocrine cells secrete hormones into blood vessels; exocrine cells secrete 
pancreatic enzymes into the pancreatic duct. Pancreatic cancer may arise from these cells 
and disrupt any of their functions. 
 
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest epithelial 
malignancies and develops from cells lining small tubes called ducts. These carry 
the digestive juices, which contain enzymes, into the main pancreatic duct and 
then into the duodenum.  
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3.1 Pancreatic ductal adenocarcinoma pathogenesis  
 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of 
cancer-related deaths. The incidence and death rates continue to increase and 
PDAC is predicted to become the second most frequent cause of cancer-related 
death by 2030 (2), making this disease a major priority in public health care. The 
prognosis of PDAC is poor, with an overall 5-years survival rate of less than 5% 
after diagnosis, which is often made when metastatic events have occurred. More 
than 85% of patients who undergo surgical resection of small pancreatic tumour 
with clear surgical margins and no evidence of metastasis, die from metastasis 
within 5 years (3, 4). PDAC evolves from precursor lesions that, in the context of 
their genetic features, define the genetic progression model of pancreatic 
carcinogenesis (5). Early disease histology manifests as several distinct types of 
precursor lesions: the microscopic pancreatic intraepithelial neoplasia (PanIN), 
followed by the macroscopic cysts such as the intraductal papillary mucinous 
neoplasm (IPMN) and mucinous cystic neoplasm (MCN). The non-invasive 
PanIN lesions were classified into three grades according to the extent of 
cytological and architectural atypia (Fig. 2): PanIN-1A and PanIN-1B show low-
grade of dysplasia; PanIN 2 presents an additional loss of polarity, cell extension 
and hyperchromasia with papillary formation; and PanIN3 represents advanced 
lesions with severe nuclear atypia, luminal necrosis and manifests epithelial cell 
budding into the ductal lumen (6, 7). Most recently, this classification has been 
replaced by a two-tier low-grade (PanIN-1 and PanIN-2) and high-grade (PanIN-
3) classification, which recognizes that the latter lesions are those with the 
greatest biological potential for progression and these lesions should be studied 
for early detection (8). Low-grade lesions are frequently observed in normal adult 
pancreas or patients with chronic pancreatitis and are associated with a low risk of 
developing PDAC. High-grade PanIN3 lesions, instead, are almost exclusively 
found in patients with invasive PDAC (9, 10).  
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Fig. 2: Progression model of PDAC. From left to right: Normal duct epithelium 
progresses to cancer through defined precursors (PanINs). The inactivation of p53, DPC4, 
and BRCA2 occurs in the late stage; the inactivation of p16 gene at an intermediate stage; 
the overexpression of HER-2/neu and point mutations in the K-ras gene occur in early 
stage. Adapted from (6).   
Since most cases of PDAC become clinically evident at advanced stages, the 
identification of high-risk precursor lesions has provided an essential framework 
to define the genomic features that drive cancer and develop effective screening 
and targeted therapies for earlier stage of disease (11).  
3.2 Genetic characteristics of PDAC 
Studies of next generation sequencing and computational biology have 
transformed our understanding on genetic alterations associated with the genesis 
and progression of PDAC, highlighting several mutations, epigenetic alterations, 
gene expression changes, and chromosomal rearrangements (12). Recent studies 
of whole-exome sequencing have reaffirmed the signature mutations of human 
pancreatic cancers, including oncogenic mutations of KRAS and the frequent 
inactivation of TP53, SMAD4 and CDKN2A tumour suppressors (13,14). These 
analyses also identified additional novel recurrent mutations in PDAC that 
converge on some pathways and processes, including Notch, Hedgehog, b-
catenin, chromatin remodelling, and DNA repair pathways (15). Over 90% of 
PDACs are driven by early KRAS mutations, which lead to constitutive activation 
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of the molecule (16). Activated KRAS signals through a phosphorylation cascade 
of RAF, MEK and ERK or PI3K/AKT/mTOR leading to the transcription of 
proliferation genes. Pancreatic cancer lacking KRAS mutations shows activation 
of RAS through an upstream signalling receptor, such as EGFR, and in a small 
fraction of patients oncogenic activation of the downstream B-RAF molecule is 
detected (17). Histologically, PDAC is characterized by a dense stroma content 
including fibroblasts, hyaluronic acid (HA), collagen and other extracellular 
matrix proteins, inflammatory cells and cancer stem cells. There are conflicting 
opinions whether the stroma supports malignancy or acts as a protective barrier. 
However, increasing evidence has proved that the tumour stroma impairs drug 
delivery and supports an immunosuppressive tumour microenvironment playing a 
key role in the development of PDAC (18).  
3.3 Cancer stem cell concept 
Cancer stem cells (CSCs) have been intensively studied for decades. The first 
concept was that CSCs constituted a subset of cells in malignant cell population 
with an exclusive ability to create endless copy of themselves through self-
renewal (19, 20). This concept offers a possible explanation for disease relapse 
following therapy, even with effective treatments that induce initial tumour 
regression. CSCs are often more resistant to treatment than the more differentiated 
tumor cells (21, 22, 23). As a consequence, the tumour is apparently eliminated 
after therapy, but it grows back because the rare CSC population has survived. 
This points out the urgent need to discover CSCs-targeted therapies to prevent 
recurrence. The acquired resistance to therapy is driven, in part, by intratumoural 
heterogeneity, that is the phenotypic diversity of cancer cells within a single 
tumour mass (24). At least two models have emerged trying to explain the 
heterogeneity and the cancer stem cell evolution. The first one concerns the 
expansion of an initially mutated or epigenetically altered progenitor cell that 
gains a proliferative advantage over its normal counterparts (25) (Fig 3). The 
initial clone can produce distinct subclones controlled by the immune system or 
surrounding environment. In the first phase of cancer evolution (phase I), tumour 
stem cells are pre-malignant. If one or more subclones undergo sufficient changes 
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to acquire malignant potential, the tumour develops. At phase II, the neoplastic 
stem cells become cancer stem cells. However, the other neoplastic subclones and 
their stem cells may remain and continue to generate additional pre-malignant or 
malignant subclones.   
 
Fig 3: Model of cancer stem cell evolution. The normal stem or progenitor cell produces 
different subclones. In phase I the stem cells are pre-malignant. The accumulation of 
mutations in one or more subcolones gives rise to the tumour. At phase II neoplastic cells 
become cancer stem cells. Adapted from (25). 
The second proposed model concerns the concept of CSCs as a subpopulation of 
neoplastic cells in the bulk of the tumour that serves as a critical driver of tumor 
progression (25) and undergoes a biological program termed epithelial-to-
mesenchymal transition (EMT) (26). This program gives phenotypic changes to 
tumour cells through epigenetic modifications, thereby carcionoma cells lose 
many of their epithelial characteristics such as the epithelial cell junctions and 
apical-basal polarity, and acquire mesenchymal features, exhibiting an elongated, 
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fibroblast-like morphology and increased migration and invasion (Fig. 4) (27, 28). 
Moreover, the induction of EMT program in epithelial tumour cells increases their 
tumour-initiating ability (29) and confers them resistance to many therapeutic 
agents (30, 31). 
 
Fig. 4: Changes associated with the activation of the epithelial-to-mesenchymal transition 
(EMT) program. Adapted from (31). 
3.4 Pancreatic CSCs 
An increasing number of studies indicate that several tumors, including PDAC, 
contain a subset of tumorigenic CSCs, which drive tumor initiation, metastasis 
and resistance to radio-and chemotherapy (32-35). Pancreatic CSCs have been 
first described in 2007 by Li et al. (36). The authors showed that pancreatic cancer 
cells with the CD44+/CD24+/ESA+ phenotype (0.2–0.8%) possessed a 100-fold 
increased tumorigenic potential compared with non-tumorigenic markers-negative 
cancer cells; only a small fraction of CD44+/CD24+/ESA+ cells was sufficient to 
give rise to tumours histologically indistinguishable from the primary human 
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tumour of derivation. In PDAC, as in other solid tumours, CSCs possess the 
exclusive ability to recapitulate the parental tumour upon transplantation into 
immunodeficient mice (37). Although CSCs bear cell-intrinsic stemness features, 
it has been shown that these cells are also affected by the surrounding 
microenvironment which contributes to their aggressiveness, metastatic activity, 
and drug resistance (38,39). For this reason, it is important to study CSCs in the 
context of their niche and to develop models that recapitulate the heterogeneity of 
primary tumours and the surrounding environment. Increasing efforts have been 
made to design in vitro cultures and in vivo xenograft models from resected 
tumours (40, 41). Patient-derived xenograft (PDX) models have been obtained 
from PDAC and have been shown to replicate the characteristics of the primary 
tumour including genetic features and cellular heterogeneity (42). In the past 
years, pancreatic CSCs have been identified by a variety of biomarkers, such as 
CD44, EPCAM, CD133, ALDH1 and hepatocyte growth factor receptor CMET 
(43). Although the number of CSC biomarkers is still increasing, their expression 
is variable because it is affected by culture conditions and response to treatment, 
and is not exclusively linked to a CSC phenotype (44). Recently, an intrinsic 
autofluorescent phenotype of PDAC CSCs has been identified and used to isolate 
and characterize these cells (45). It has been demonstrated that the 
autofluorescence is derived from riboflavin actively sequestered in cytoplasmic 
vesicles by an ATP-dependent process. Interestingly, only in digested tumours 
and early passage in vitro cultures from these tumours, the autofluorescent 
population was detected, but not in cell lines such as Panc1. This specific 
autofluorescent phenotype allowed the identification and purification of PDAC 
CSCs by fluorescence-activated cell sorting and confocal microscopy, without the 
use of antibodies and independently of expression of cell surface markers. 
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3.5 Treatment and chemoresistance in pancreatic cancer 
Although different therapeutic strategies for treating pancreatic cancer are 
available, the chemotherapy remains the first choice, especially for advanced 
tumour stages. Numerous efforts have been made to improve the treatment in 
PDAC (46), but unfortunately, the therapeutic response is still largely ineffective 
and not durable (47). The failure is due to many factors, including extrinsic (48) 
or intrinsic (49) resistance to conventional approaches of chemotherapy. For a 
long time, the standard of care for PDAC has been the deoxycytidine (dCyd) 
nucleoside analog, gemcitabine (GEM) (50). The metabolite GEM 3-phosphate 
interferes with tumor growth through incorporation into DNA or alternatively, 
GEM diphosphate can interfere with DNA synthesis and thus tumor growth 
through inhibition of ribonucleotide reductase. Like other anticancer agents, GEM 
induces reactive oxygen species (ROS) generation (51), cell cycle blocking in S 
phase (52) and apoptosis of human pancreatic carcinoma cells correlated with Bcl-
2 content (53). Despite its effective anticancer activity, GEM suffers from various 
drawbacks, such as a rapid deamination to the inactive metabolite 2’,2’-
difluorodeoxyuridine by cytidine deaminase, resulting in a short in vivo half-life, 
and then it must be administered at very high dose. Indeed, this therapy only 
confers a marginal survival advantage to patients, showing efficacy in less than 
20% of them (54). Furthermore, a large number of patients is resistant to these 
therapies mainly because the dense tumour stroma functions as a barrier and 
extrinsic resistance (55). Small improvements in short-term survival have been 
achieved by the addition of erlotinib (56) or capecitabine (57) to GEM, but the 
benefit is in the order of weeks. Recently, more encouraging results have emerged 
with combined treatment of GEM/nab-paclitaxel, an albumin-based formulation 
of the chemotherapeutic drug paclitaxel, (58) and the FOLFIRINOX, a potent 
chemotherapy regimen made up of four drugs, oxaliplatin, irinotecan, 
fluorouracil, and leucovorin (59). Although these treatments improve median 
survival of patients, they are highly toxic and don’t allow a long-term survival. As 
a consequence, it is crucial to understand the mechanisms of resistance for the 
design of drug combinations in order to achieve successful therapies. 
 18 
3.6 The prodrug approach: a successful tool for improving drug stability 
The prodrug approach is a strategy of molecular modification widely used to 
optimize the physical, chemical and pharmacological properties of drugs in order 
to improve their solubility and pharmacokinetic features. A prodrug is an active or 
slightly active compound containing the native drug that undergoes an in vivo 
transformation through chemical or enzymatic cleavage, enabling the release of 
the active molecule at specific sites (Fig. 5) (60). 
 
Fig. 5: Bioactivation of prodrugs by enzymatic or chemical transformations. 
Prodrugs are classified into two classes, carrier-linked prodrugs and 
bioprecursors. Carrier-linked prodrugs can be divided in bipartite prodrugs, in 
which the carrier is directly linked to the parental drug, and tripartite prodrugs, in 
which the carrier is linked to the drug through a spacer. Carriers are generally 
attached by chemical groups such as amide, carbamate, ester, carbonate, 
phosphate and others. Mutual prodrugs, instead, are a type of carrier-linked 
prodrug in which both compounds are active and each acts as the carrier to the 
other. The bioprecursors are inactive compounds that are rapidly converted to an 
active drug after metabolic reactions (61). Some properties, including poor 
aqueous solubility, chemical instability, low half-life, fast metabolism or problems 
related to drug formulation and delivery are resolved using the prodrug approach 
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(62, 63, 64). For example, a series of lipophilic prodrugs were synthesized by 
linking the 4-amino group of GEM with valeroyl, lauroyl or stearoyl linear acyl 
derivatives to increase the stability and the bioavailability of the drug (Fig. 6).  
 
Fig 6: Gemcitabine and 4-(N)-acyl-gemcitabine prodrug structure. 
This increase in stability occurs because the acyl moiety chemically protects the 
amidic group in the N-4 position of cytosine that is rapidly metabolized in plasma. 
Studies of differential scanning calorimetry have shown that the lipophilic 
prodrugs are more able than pure GEM to interact with lipid bilayers, thus 
modulating its transport and release inside the cellular compartments (65). 
3.7 Targeted drug delivery system for pancreatic cancer  
The selective delivery of therapeutic agents to their cellular targets represents the 
main objective of the current investigations for effective treatment of pancreatic 
cancer. Several approaches have been utilized, such as liposomes, polymers, and 
micelles carrying anti-cancer drugs with the aim of passive targeting through 
enhanced permeation and retention effects (66). The most known carrier for drug 
delivery system is the liposome, a single lipid bilayer vesicle which, because of its 
structure, can encapsulate a wide range of molecules with hydrophilic, 
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amphiphilic or lipophilic characteristics. Furthermore, its phospholipidic 
framework ensures complete biocompatibility (67). However, lipid-based carriers 
are quickly cleared from the bloodstream by the reticuloendothelial system. To 
overcome this issue, different chemical modifications of carriers with synthetic 
polymers have been frequently carried out (68). One of the most successful 
modification is the coating with polyethylene glycol (PEG), a non-toxic, non-
immunogenic, non-antigenic and highly water soluble polymer. The use of PEG 
has several advantages: it can “mask” the agent from the immune system, 
reducing immunogenicity and antigenicity, and increase its hydrodynamic size, 
prolonging the circulatory time. Furthermore, PEGylation can also provide water 
solubility to hydrophobic drugs (69). An example is doxorubicin in PEG-coated 
liposomes, which is widely used in clinical practice to treat solid tumours, 
including breast, pancreatic and prostate cancer (70). Over the years, the research 
in liposome field has been oriented towards the development of systems capable 
of specifically recognizing the target cells. This strategy involves the use of a 
targeting molecule able to drive the nanosystem directly on the target cells by 
recognition of specific molecules expressed on cell surface (Fig. 7) (71).  
 
Fig. 7: Schematic representation of active targeting strategy of drug delivery.  
According to this strategy, different liposomes are decorated with peptides, 
aptamers, antibody or small molecules (72, 73). It has been demonstrated that 
pancreatic cancer cells overexpress CD44, the hyaluronic acid (HA) receptor (74). 
For this reason, HA is employed as a good targeting agent to obtain liposomes 
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able to selective target and destroy pancreatic cancer cells. Furthermore, HA is a 
non-toxic, non-immunogenic and biodegradable polymer, features that render it 
an ideal candidate as targeting agent (75). 
3.8 Disulfiram and derivatives as promising anticancer drugs 
Disufiram (DSF) (Antabuse®), an irreversible inhibitor of aldehyde 
dehydrogenase, is a FDA approved drug for the treatment of alcoholism (76).  It 
has been shown that DSF acts as antitumoral drug (77, 78) and represents a 
possible anti-CSC agent in breast cancer and glioblastoma (79, 80). The 
anticancer activity of DSF has not yet been fully elucidated. Indeed, various 
mechanisms have been proposed, such as the inhibition of aldehyde 
dehydrogenase, proteasome, NF- κB, DNA methyltransferase and multidrug 
resistance p-glycoprotein activities (81). In the bloodstream, DSF is converted 
into two molecules of diethyldithiocarbamate (DDC) (Fig 8 A).  
 
Fig. 8: Anticancer mechanism of disulfiram (DSF).  A) Formation of a new chemical 
Cu(DDC)2 from DSF; B) Phases of anticancer model of DSF and DDC. 
The complex of DDC with a metal ion, usually copper or zinc, is mainly 
responsible for the anticancer activity of DSF (82). Two phases have been 
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proposed in the anticancer model of DSF and DDC (Fig. 8 B) (83). First, the 
chelation of DDC and copper generates extracellular radical oxygen species 
(ROS) inducing cancer cell apoptosis. Second, the chelation-generated compound, 
Cu(DDC)2, can easily penetrate into cancer cells, trigger the generation of 
intracellular ROS and induce cancer cell apoptosis. Despite its powerful 
anticancer activity, the development of DSF-based cancer therapy is prevented by 
different factors, such us poor solubility of DSF in biological fluid and its rapid 
degradation in the bloodstream (76). It is therefore necessary to overcome these 
limitations to develop effective anticancer therapies.  
3.9 Endocytic route and interaction modalities of molecules with cell 
membrane  
The release of drugs in cells occurs following the crossing of the plasma 
membrane barrier. Plasma membrane presents high complexity and  has a critical 
function in the cellular adhesion, communication, and division, and endocytosis 
plays an important role in the regulation of these critical functions (84).   
The uptake route of some molecules depends on their physical characteristics 
including particle size, shape and surface charge, and also on the type of cell. 
Usually, small and non-polar molecules use a passive mechanism, such as 
diffusion or facilitated diffusion, to enter into the cell without the use of energy. 
On the other hand, macromolecules use other mechanisms of transport such as 
endocytosis, in which the macromolecule that need to be internalized is 
surrounded by an area of plasma membrane, which forms a vesicle inside the cell 
containing the ingested material (85).  
3.9.1 Main pathways of endocytosis 
Endocytosis pathways can be divided into three categories namely:  
• Macropinocytosis is the invagination of the cell membrane to form a 
vesicle filled with a large volume of extracellular fluids and molecules. 
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The intracellular fate of the vesicles is cell dependent, and in the cytosol 
vesicles fuse with endosomes and lysosomes (86);   
• Phagocytosis is the internalization of solid particles such as debris or 
apoptotic cells to form an internal compartment known as phagosome, 
involving the uptake of large membrane areas (87);     
•   Receptor-mediated endocytosis, also called clathrin-mediated 
endocytosis is the most frequent endocytic pathway and is normally used 
by the cells for the specific uptake of certain substances (hormones, 
metabolites, other proteins) (88). Clathrin-mediated endocytosis involves 
the internalization of fragments of the cytoplasmic membrane in form of 
vesicles containing all of their contents  and coated with polymerized 
clathrin (Fig. 9). In particular, clathrin and cargo molecules are assembled 
into clathrin-coated pits on the plasma membrane with adaptor proteins, 
such as AP-2, that links clathrin with transmembrane receptors.  
 
 
Fig. 9: Mechanism of clathrin-dependent endocytosis. The adaptor protein AP-2 links 
clathrin with receptor, forming the clathrin-coated vesicles. Clathrin is released and 
vesicles are transported to early endosomes. 
In conclusion, the mature clathrin-coated vesicles are formed and then actively 
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uncoated and transported to early endosomes, or recycled to the plasma membrane 
surface (89). 
The vesicles can also be targeted to mature endosomes and later to compartments 
such as lysosomes. Different molecular biological tools and pharmacological 
agents have been used to selectively inhibit clathrin-mediated endocytosis (90). 
Molecular approaches include the use of RNA interference technology and the 
downregulation of the endogenous proteins involved in clathrin-mediated 
endocytosis (91). Pharmacological and chemical agents, such as chlorpromazine 
(CPM), are more advantageous than molecular approaches, because 
pharmacological inhibition prevent the entry into the cell and is not dependent on 
transfection efficiency. CPM is a cationic amphipathic drug that is believed to 
inhibit clathrin-coated pit formation through a reversible translocation of clathrin 
and its adapter proteins from the plasma membrane to intracellular vesicles (92). 
However, a major drawback of pharmacological agents is the non-specific effect, 
influencing other related processes (93).  
 
3.9.2 Lipid-raft mediated endocytosis 
The lipid-rafts are an assembly of specific lipids, usually glycosphingolipids and 
cholesterol, into a glycolipoprotein domain within the membrane bilayer (Fig.10 
A). Some proteins, for example caveolin-1, are essential in the membrane raft 
formation and function and can be found as constitutive components of rafts. 
However, caveolin-1 is not the only protein involved in raft formation, but others 
may display the scaffolding functions in caveolin-independent rafts, such as 
Reggies/flotillins (94). Lipid rafts are more ordered and tightly packed than the 
surrounding membrane, but float in the lipid bilayer (95). These specialized 
domains have been intensely studied for years (96). The highly dynamic raft 
domains are essential in signalling processes and are also sorting platforms for the 
traffic and recruitment of proteins (97) (Fig. 10 B). This recruitment in rafts takes 
place through interactions between the lipids within the raft and the 
transmembrane domain of integral proteins (lipid-protein interaction) or the lipid 
moiety of protein attached to the membrane by a lipid modification (lipid-lipid 
interaction). On the other hand, the recruitment of cytosolic proteins by protein-
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protein interactions through modular domain (e.g. SH2 domain), can take place in 
both raft and non-raft membranes (98).  
 
 
 
Fig.10: Model of lipid-raft structure and function in biological membranes. A) Lipid rafts 
are microdomains formed by sphingolipids (dark-brown structures) and cholesterol (red 
bean-shaped structures) immersed in a phospholipid bylayer (light-brown structures); B) 
Selective recruitment of proteins in rafts. This process occurs through lipid-protein 
interaction or lipid-lipid interaction. The recruitment of cytosolic proteins by protein-
protein interactions can occur in both raft and non-raft membranes. Proteins included in 
rafts are in blue (integral membrane proteins), light brown (GPI-anchored proteins) or 
pink (acylated proteins such as Src family kinases or Ras); Proteins excluded from rafts 
are in yellow. Adapted from (98). 
It is now widely accepted that lipid rafts possess an internalizing capacity 
activated by some ligands through multiple endocytic mechanisms (99). These 
mechanisms include three distinct raft-associated routes that are dependent or 
independent of dynamin (100). Dynamin-dependent endocytosis can involve or 
not the caveolin-1 while the third raft-associate route, which is both dynamin and 
caveolin independent, requires the fotillin-1 and CDC42. The lipid-raft domains 
are also used by lipophilic nanoparticle substances to enter directly into the 
plasma membrane through mechanisms of lipid particle fusion and lipid mixing, 
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and subsequently trafficked to the cytosol (101). Different chemical agents, such 
as methyl-b-cyclodextrins (MbCD), can modify the lipid rafts content in the 
membrane, extracting cholesterol from these domains (102). MbCD is a cyclic 
heptasaccharide consisting of external hydrophilic structure and internal 
hydrophobic cavities, and remove cholesterol from lipid domain due to its high 
affinity towards it (103). The process of selective cholesterol removal is 
dependent on MbCD concentration. At high concentrations, MbCD also removes 
phospholipids. 
 
3.9.3 Membrane nucleoside trasporter-mediated uptake  
The uptake of natural nucleosides and various nucleoside-derived drugs is 
mediated by membrane transport proteins, belonging to two families of 
transporters, concentrative nucleoside transporters (CNTs) and equilibrative 
nucleoside transporters (ENTs) (104). Both families consist of three or four 
members, respectively, which differ in their energy requirements and the substrate 
selectivity. The expression of these transporters can be regulated, and their tissue 
distribution is not uniform in the various tissues (Table 1). The vast majority of 
CNT and ENT transporters is localized in the apical and basolateral membranes, 
where they can play physiological roles, such as the modulation of extracellular 
and intracellular adenosine concentrations (105). All three CNTs transport uridine 
but exhibit different preferences for other molecules. CNT1 exhibits selectivity 
for pyrimidine nucleosides, CNT2 for purine nucleosides, and CNT3 for both 
purine and pyrimidine nucleosides (106, 107). Moreover, ENT1, ENT2 and ENT3 
possess similar selectivity for purine and pyrimidine nucleosides, while ENT4 is 
uniquely selective for adenosine, but also transports organic cations (108). 
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Protein name Transport type Predominant tissue/ subcellular 
distribution 
CNT 1 Concentrative 
(sodium/nucleoside 1:1) 
Liver, kidney, small intestine. Localization: primarily 
plasma membrane 
CNT 2 Concentrative 
(sodium/nucleoside 1:1) 
Heart, skeletal muscle, liver, kidney, intestine, 
pancreas, placenta and brain. Localization: Primarily 
plasma membrane.  
CNT 3 Concentrative 
(sodium/nucleoside 2:1 or 
proton/nucleoside 1:1) 
Mammary gland, pancreas, bone marrow, trachea 
and intestine. Localization: primarily in plasma 
membrane, but intracellular in some cell types and 
splice variants.  
ENT 1 Facilitated diffusion Widely expressed, primarily in the plasma 
membrane but also in nuclear and mitochondrial 
membranes.  
ENT 2 Facilitated diffusion Skeletal muscle Localization: primarily plasma 
membrane but also in nuclear membranes.  
ENT 3 Facilitated diffusion Widely expressed, intracellular (late 
endosomal/lysosomal and mitochondrial 
membranes).  
ENT 4 Unclear, possibly proton 
linked 
Heart, brain, and skeletal muscle. Localization: 
Primarily plasma membrane  
Table 1: List of CNT and ENT nucleoside transporters, their transport type and 
predominant tissue/ subcellular distribution. 
Multiple factors, including cell cycle phases and cytokines, regulate the 
expression of nucleoside transporters in human and other mammalian cells (109). 
Moreover, these transporters have also clinical significance. Nucleoside 
transporters are responsible for the cellular uptake of several nucleoside-derived 
drugs used in cancer chemotherapy, such as GEM (110, 111).  Thus, the 
nucleoside transporter content of cells can affect the response to treatment. ENT1 
is considered to be predominantly involved in GEM transport (112). The 
relationship between ENT1 and GEM has been widely studied and, during the last 
decade, several pre-clinical studies confirmed that the overexpression of ENT1 
might serve as a predictive biomarker for the efficacy of GEM (113, 114). In 
particular, Giovannetti et al. demonstrated that in PDAC patients treated with 
GEM, the high expression of ENT1 was associated with a significant 
improvement in overall survival (115). Several pharmacological agents can be 
used to block the activity of nucleoside transporters, such as dipyridamole that can 
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inhibit the antiproliferative effect of GEM in various cancer cell lines (116). 
3.9.4 Fatty acid translocase/CD36-mediated uptake and regulation of fatty 
acid transport 
Some evidence shows that long-chain fatty acids are actively transported across 
cell membrane by specialized proteins instead of passive diffusion (117). The 
proteins involved in the fatty acids transport and trafficking include the fatty acid 
transport proteins (FATPs) or fatty acid binding proteins (FABPs) that are 
expressed most abundantly in tissues involved in active lipid metabolism (118). 
The CD36 or fatty acid translocase protein mediates the uptake of fatty acids in a 
variety of cell types and its increased expression is correlated with elevated uptake 
of fatty acids (119, 120). In particular, CD36 is a heavily glycosylated integral 
membrane protein with high affinity for long chain fatty acids. The role of CD36 
in cellular fatty acid uptake was identified in 1993 (121) and is now supported by 
strong evidence generated in CD36 deficient humans (122). Polymorphisms in the 
CD36 gene have been linked with alterations in plasma lipid levels, such as 
abnormal serum fatty acids and low-density lipoproteins (LDL), and with 
increased susceptibility to the metabolic syndrome (123). In the context of 
tumours, CD36 has previously been described in the regulation of endothelial cell 
function in multiple types of cancer including breast, melanoma, and glioblastoma 
(124). For example, in breast cancer the repression of CD36 is involved in the 
regulation of pro-tumorigenic phenotypes, including angiogenesis, cell-
extracellular matrix interactions and adipocyte differentation. It has also been 
demonstrated that CD36 recognizes a variety of ligands in the tumour 
microenvironment. For example, it is responsible for the inhibition of vascular 
growth in glioblastoma through the interaction with vasculostatin, inducing the 
endothelial cell apoptosis (125). Interestingly, some studies on glioblastoma 
provide evidence that CD36 was particularly enriched in CSCs and was able to 
functionally distinguish cells with self-renew capability. Furthermore, CSCs 
selectively used the scavenger receptor CD36 to promote their maintenance (126). 
Given the observation that CD36 expression was associated with self-renewal and 
CSC marker expression, its inhibition resulted in concomitant loss of self-renewal 
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and tumour initiation capacity. The fatty acids uptake mediated by CD36 is 
inhibited in a variety of cell types using the membrane-impermeable 
sulfosuccinimidyl oleate (SSO) (127). This molecule reacts rapidly to form stable 
bonds primarily with amino groups in lysine side chains and the negative charge 
of sulfonate group contribute to restrict the membrane permeability (128). 
3.10 Apoptosis and molecular targeting therapy in cancer 
 
Apoptosis is the programmed cell death with distinct biochemical and genetic 
pathways that play a critical role in the development and homeostasis of normal 
tissues (129).  Apoptosis is triggered by proteases, called caspases which are 
typically activated in the early stages of apoptosis. These enzymes cleave key 
cellular components that are required for the normal cellular functions including 
structural proteins in the cytoskeleton and nuclear proteins such as DNA repair 
enzymes (130). During the apoptotic process, cells display distinctive features. 
Generally, the cell begins to shrink following the cleavage of lamin and actin 
filaments, and the breakdown of chromatin leads to nuclear condensation. After 
these changes, in order to promote the phagocytosis by macrophages, apoptotic 
cells undergo plasma membrane modifications. One of these modifications is the 
translocation of phosphatidylserine from the inside of the cell to the outer surface. 
The last stages of apoptosis are characterized by the formation of membrane blebs 
and small vesicles, called apoptotic bodies (131). The mechanisms of apoptosis 
are highly complex and evolutionarily conserved (132). There are two main 
apoptotic pathways: the extrinsic or death receptor pathway and the intrinsic or 
mitochondrial pathway (Fig. 11). The extrinsic pathway that requires an external 
stimulation, occurs via a death receptor family member located on the plasma 
membrane, such as different tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) receptors, FAS or TNF receptor 1. After ligand binding, 
the death receptors activate caspases that lead to a cleavage of substrates and a 
rapid cell death (133, 134, 135). The intrinsic apoptotic pathway, which is often 
deregulated in cancer, is activated by a wide range of stimuli, such as DNA 
damage and endoplasmic reticulum stress. Cell stresses lead to one crucial event 
that is the mitochondrial outer membrane permeabilization (MOMP) triggered by 
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BAX and BAK activity, which are directly activated by the BH3-domain of BCL-
2 (136). Following mitochondrial permeabilization, cytochrome C and other 
mitochondrial proteins such as SMAC are released into the cytosol. Cytocrome C 
interacts with apoptotic protease activating factor 1 (APAF1), triggering the 
apoptosome assembly, which activates caspase-9. Active caspase-9, in turn, 
activates caspase-3 and caspase-7, leading to apoptosis (137, 138). Mitochondrial 
release of SMAC leads to apoptosis by blocking the X-linked inhibitor of 
apoptosis protein (XIAP) and thus preventing its binding to caspases. This allows 
normal caspase activity to proceed (139). In addition to cytocrome C and SMAC, 
mitochondria also release other molecules, such as apoptosis inducing factor 
(AIF) that may promote caspase-independent cell death (140). AIF is a 
flavoprotein located in mitochondria with NADH oxidase activity. When 
apoptosis is induced, AIF traslocates from mitochondria to the cytosol as well as 
to the nucleus. It has been demonstrated that when added to purified nuclei, AIF 
induces partial chromatin condensation as well as the DNA fragmentation in a 
caspase-independent fashion (141). 
 
Fig. 11: Extrinsic and intrinsic apoptotic signalling pathway. Adapted from (132). 
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There is an additional apoptotic pathway that involves T-cell cytotoxicity and 
granzyme A or B. Granzyme A can induce a caspase- independent cell death 
pathway through single strand DNA damage (142), whereas granzyme B pathway 
involves the activation of initiator caspase, which in turn will activate the 
executioner caspase-3 (143). Defect in apoptosis can promote tumorigenesis, 
allowing the neoplastic cells to survive, subverting the need for exogenous 
survival factors and providing protection from oxidative stress and hypoxia. These 
events lead to the accumulation of genetic alterations that deregulate cell 
proliferation and promote angiogenesis and invasiveness during tumour 
progression. Thus, the evasion of apoptosis is an evident hallmark of cancer (144). 
It has been demonstrated that the inhibition of cell death, in combination with 
mitogenic oncogenes, can promote cancer in mouse models (145, 146). Moreover, 
many oncogenic pathways can inhibit apoptosis, whereas tumour suppressors, 
such as p53 can induce apoptosis (147). It is frequently observed the positive 
correlation between apoptotic sensitivity and therapeutic efficacy in cancer cells 
(148). However, although the inhibition of apoptosis contributes to promote 
cancer, tumor cells are not often inherently resistant to apoptosis. Indeed, 
paradoxically, high levels of apoptosis have been shown to correlate with poorer 
prognosis in some cancers, whereas high levels of anti-apoptotic proteins correlate 
with better prognosis (149, 150). The ability of the therapy to induce apoptosis by 
targeting the overexpressed anti-apoptotic proteins or by stimulating the pro-
apoptotic molecules expression, is crucial for the success of each therapeutic 
strategy.   
 
3.11 The role of autophagy in cancer disease 
Autophagy is an intracellular catabolic process by which damaged material, 
macromolecules and organelles, are degraded by lysosomes or vacuoles and then 
recycled. This process involves the formation of double-membrane vesicles 
known as autophagosomes that engulf proteins and organelles for delivery to the 
lysosome. The resulting structure is an autophagolysosome and its content is 
degraded by lysosomal hydrolases (Fig. 12) (151). Autophagy is controlled by 
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highly regulated events and it occurs at basal level in all cells or is induced by 
diverse signals and cellular stresses (152).   
 
Fig. 12: Schematic representation of the various steps of autophagy.  
The formation and turnover of the autophagosome requires the activation of some 
autophagy related genes (ATGs) and is divided into distinct stages; the initiation 
begins with the activation of ATG complex that activates a class III PI3K 
complex comprising VPS34, ATG14 and other proteins, all of which are 
scaffolded by the tumour suppressor Beclin 1 (153). The expansion of the 
autophagosome membrane involves the ATG5-ATG12 complex in conjugation 
with ATG16, and members of LC3 family are conjugated to the 
phosphatidylethanolamine (PE) and recruited to the membrane. ATG4B with 
ATG7 conjugates LC3I and PE to form LC3II. This lipidic form of LC3 is used as 
an autophagosome marker (154). Finally, the autophagosome fuses with the 
lysosome and the content is degraded and molecular precursors are recycled. The 
role of autophagy in cancer is controversial and it is likely dependent on the 
tumour type and cellular context (155, 156). Numerous evidences suggest that 
autophagy prevents cancer development (157). Conversely, in an established 
cancer, increased autophagic flux often induces tumour cell growth and survival 
(158). For this reason, interventions to both stimulate and inhibit autophagy have 
been proposed as cancer therapies. Despite this potential confusion on the role of 
autophagy in cancer, the vast majority of studies is focused on inhibiting 
autophagy and evaluating its effect on clinical outcome (159, 160). Animal 
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models with a specific expression of some oncogenes have been shown to develop 
tumours that regress after genetic or pharmacological inhibition of autophagy. 
Similarly, in vitro studies, genetically engineered mouse models (GEMMs) and 
patient-derived xenograft (PDX) mouse models have shown the increased 
antitumour effects when anticancer drugs are combined with genetic or 
pharmacological inhibitors of autophagy (161, 162, 163). The most used 
autophagic inhibitor is chloroquine that deacidifies the lysosome and blocks the 
fusion of autophagosomes with lysosomes, thus preventing cargo degradation 
(164). Other studies have reported the potential role of autophagy in the ability of 
cancers to develop resistance to chemotherapy. Moreover, the inhibition of 
autophagy could reverse acquired resistance to drugs (165).  
3.12 Cancer as a cell cycle defect 
Cell cycle, the process by which cells progress and divide, is at the centre of the 
tumour. In normal cells, the cell cycle is controlled by different signalling 
pathways by which a cell grows, replicates its DNA and divides. There are four 
phases in the cell cycle (166) (Fig. 13):  G1 phase in which the cell grows and 
prepares itself to synthesize DNA; S or synthesis phase, in which the cell 
synthesizes DNA; G2 phase consists in the preparation for cell division which 
occurs in the M phase or mitosis. The various steps in the cell cycle are tightly 
regulated by arrest at G1 or G2 checkpoints and multiple molecular pathways, 
including cyclin dependent kinases (CDKs) and their regulatory inhibitors. These 
enzymes are activated by forming complexes with cyclins, a group of regulatory 
proteins only present for a short period in the cell cycle (167). Inhibitors of CDKs, 
such as p21WAF1/CIP1 and p27Kip1 induce the arrest of cell proliferation by 
negatively regulating cell cycle checkpoints (168). In normal conditions, the 
regulatory proteins act by controlling cell growth and inducing the death of 
damaged cells. In cancer, genetic mutations cause the malfunction or disruption of 
the cell cycle control mechanisms, resulting in uncontrolled cell proliferation and 
then in the tumour development (169).   
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Fig. 13: Phases of cell cycle: G0 phase- Quiescent state; G1 phase-preparation for DNA 
synthesis; S phase- DNA replication; G2 phase- preparation for mitosis; M- mytosis.  
Two types of gene play an important role in the cell cycle and in cancer 
development: oncogenes (e.g. Ras, c-Myc) and tumour suppressor genes (e.g. p53 
and Rb) (170). For example, p53 has been described as “the guardian of the 
genome” (171), since its major role is to prevent the genome of mutated cells 
from proliferation. Mutations of tumour suppressor genes, which control the cell 
cycle checkpoints, allow damaged cells to progress through the cell cycle, giving 
rise to the tumour. The development of cell cycle-based cancer therapies is widely 
studied, in order to inhibit the growth of cancer cells. In general, DNA damaging 
drugs such as GEM induce cell cycle arrest in S or G2 phases in a manner 
regulated by ChK1 kinase (172). The arrest allows the repair of DNA before the 
cell progresses through the cell cycle.  
 
 
 
 
 
 35 
4. AIM OF THE STUDY 
PDAC is the fourth leading cause of cancer-related deaths due to disease 
presentation at an advanced stage, early metastasis and generally a very limited 
response to radio and chemotherapy. The current therapeutic strategies are often 
unsatisfactory. For a long time, the first-line therapy has been GEM that confers 
only a marginal survival advantage to patients. Small successes in medial survival 
have been achieved with combined treatment of GEM/nab-paclitaxel and the 
FOLFIRINOX. However, these therapies are highly toxic and a long-term 
survival is still a rare case. The absence of effective treatments for PDAC prompts 
researchers to supplement the current therapies and investigate urgently new 
therapeutic strategies. An increasing number of studies indicate that PDAC is 
sustained by a distinct population of quiescent cells, which maintain a 
mesenchymal phenotype and express specific surface markers of CSCs. The 
functional properties of CSCs are self-renewal, anchorage-independent growth, 
long-term proliferative capacity, chemo- and radio-resistance. These cells are also 
essential for metastatic behaviour and are responsible for the disease relapse 
following treatment, even with effective drugs that induce initial tumour 
regression (e.g. nab-paclitaxel). In this context, a major impact on tumour 
progression is only possible with the use of combined treatments against both 
differentiated cells, that represent the bulk of the tumour, and CSCs. In this work, 
we investigate novel treatment strategies in order to identify new ways for 
targeting CSCs. Given their particular resistance to traditional chemotherapy, the 
specific killing of CSCs represents one of the most important challenges to 
eradicate the tumour and prevent recurrence.  
Based on the above considerations, the main objectives of my PhD project can be 
summarized as follows:  
• Evaluate the antitumor activity of lipophilic prodrugs obtained by 
conjugating GEM with the fatty acid chains, (4-(N)-lauroyl-GEM, C12 
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GEM) and (4-(N)-stearoyl-GEM, C18 GEM), on pancreatic cancer cell 
line and the derived CSCs; 
• Elucidate the cell inhibition mechanisms induced by the drugs, such as 
apoptosis, autophagy and cell cycle analysis, and the involved intracellular 
uptake mechanisms; 
• Evaluate the effectiveness of a valid approach of drug delivery system 
which include PEGylated liposomes containing DSF or Cu(DDC)2 and 
liposomes selective for pancreatic CSCs, using HA as targeting agent.  
The antitumor activity of the various DSF formulations has been 
investigated on CSCs derived from PDAC cell lines or patients. 
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5. MATERIALS AND METHODS 
5.1 Cell lines and primary human pancreatic cancer cells 
The human Panc1 PDAC cell line was grown in RPMI 1640 supplemented with 
10% FBS, 2 mM glutamine, and 50 µg/ml gentamicin sulfate (Gibco, Life 
Technologies). Adherent cells were maintained in standard conditions for a few 
passages at 37° C with 5% CO2. Panc1 CSCs were generated as previously 
described (173) and cultured in CSC medium, i.e. DMEM/F-12 without glucose 
(US biological Life Sciences) supplemented with 1g/l glucose, B27 (Gibco, Life 
Technologies), 1 µg/ml Fungizone (Gibco, Life Technologies), 1% 
penicillin/streptomycin (Gibco, Life Technologies), 5 µg/ml heparin (Sigma), 20 
ng/ml EGF (epidermal growth factor, Peprotech), and 20 ng/ml FGF (fibroblast 
growth factor, Peprotech). Human PDAC tissues were obtained with written 
informed consent from all patients and expanded in vivo as patient-derived 
xenografts (PDX) (174). PDXs- derived tumours (A6L, 12556) were minced, 
enzymatically digested with collagenase (STEMCELL Technologies) for 90 
minutes at 37 °C, and after centrifugation for 5 minutes at 1200 rpm, cell pellets 
were resuspended and cultured in RPMI (Invitrogen) supplemented with 10% 
FBS and 50 U/mL penicillin– streptomycin. PDX-derived tumours were used in 
culture until passage 10. Circulating tumour cells (CTC)- derived cultures (C75, 
C76, C102) were established from blood of PDAC patients. Briefly, blood sample 
was incubated with a cocktail of antibody-coated beads (CELLection Pan Mouse 
IgG Dynabeads, Invitrogen) for 20 minutes, and run through the IsoFlux machine 
(Fluxion). Cells are positively isolated from the sample using an immunomagnetic 
capture device IsoFlux®. Isolated cells were then released from the beads by 
incubating for 20 minutes with Release Buffer and cultured in RPMI 
supplemented with 10% FBS and 50 U/mL penicillin– streptomycin. 
5.2 Drugs preparation 
 
All compounds tested on our cell models were provided from University of Turin 
(in collaboration with Prof. S. Arpicco). GEM was dissolved in distilled water at 
the final concentration of 3mM and stored at -80°C. C12 GEM and C18 GEM 
 38 
were dissolved in ethanol at the final concentration of 2.2mM and 1.9mM 
respectively, and stored at -20°C. 
DSF was dissolved in ethanol, DSF conjugated with zinc (Zn(DDC)2), or copper 
(Cu(DDC)2), or iron (Fe(DDC) 2) were dissolved in DMSO and stored at -20°C. 
The liposomes were prepared by a lipid film hydration-extrusion method (DSF-
5%PEG liposome) or using ion gradient method (Cu(DDC)2-5%PEG liposome, 
Cu(DDC)2-5% HA 4800 liposome, Cu(DDC)2-5% HA 17000 liposome, 
Cu(DDC)2-2%PEG-3%HA 4800 liposome, Cu(DDC)2-2%PEG-3%HA 17000 
liposome). Lipid and drugs (DSF or CuCl2) were dissolved in chloroform and 
evaporated by rotary evaporator until the formation of a thin layer lipid film. After 
hydration, liposomes were then extruded (Extruder, Lipex, Vancouver, Canada) 
under nitrogen, through 220 nm polycarbonate filters (Costar, Corning 
Incorporated, NY) using pressure of 10 bar. Liposomal preparations were purified 
from unencapsulated DSF or CuCl2 through chromatography on a Sepharose CL-
4B columns, eluting with HEPES buffer for DSF or SHE buffer for CuCl2. To 
obtain liposomes containing Cu(DDC)2 complex, a solution of the active 
metabolite of DSF (DDC) (0.25 mg/50 µl MilliQ® water) was added to liposomes 
containing CuCl2 and incubated for 25 minutes at room temperature. A drastic 
colour change, from light blue to brown, indicated the formation of Cu(DDC)2 
complex inside the liposomes. 
 
5.3 Cell viability Assay 
 
Panc1 and Panc1 CSCs were plated in 96-well cell culture plates. Viable cells 
were counted by Trypan Blue dye exclusion and 7x103 cells were seeded in each 
well and incubated at 37˚C with 5% CO2. After 24 hours, both cell lines were 
treated as following: 50µM GEM, 50µM C12 GEM and 50µM C18 GEM for 72 
hours. To determine their mechanism of intracellular transport, cells were treated 
also with different membrane entry inhibitors: dipyridamole (Sigma aldrich, 
Milan), methyl-β-cyclodextrin (MβCD, Sigma Aldrich, Milan), chlorpromazine 
(CPM, Sigma Aldrich, Milan), sulfo-N-succinimidyl oleate (SSO, Cayman). 
Moreover, the antitumor activity of other compounds was tested. Panc1 and Panc1 
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CSCs were treated for 24 hours with a range of concentrations from 0.05 to 100 
µM of the following compounds: DSF, Zn(DDC)2, Cu(DDC)2 or Fe(DDC)2, or 
liposomes (DSF-5%PEG liposome, Cu(DDC)2-5%PEG liposome, Cu(DDC)2-5% 
HA 4800 liposome, Cu(DDC)2-5% HA 17000 liposome, Cu(DDC)2-2%PEG-
3%HA 4800 liposome, Cu(DDC)2-2%PEG-3%HA 17000 liposome). At the end 
of the treatments, cell viability and the inhibitory activity were evaluated by 
Resazurin Cell Viability Assay Kit (Immunological Science). This kit detects cell 
viability by converting resazurin, a non-fluorescent dye, to resorufin, a highly red 
fluorescent dye, in response to chemical reduction of growth medium due to cell 
growth. Sixty µl of resazurin solution (10µl of resazurin and 50µl of fresh 
medium) were added in each well. After about 1 hour, the fluorescent signal was 
monitored using 535 nm excitation wavelength and 590 nm emission wavelength. 
The fluorescent signal generated from the assay is proportional to the number of 
living cells in the well. Three independent experiments were performed for each 
condition and cell viability was reported as the percentage relative to control.  
5.4 Immunoblot analysis for apoptosis 
Cells were plated in 60 mm culture plates (5x105 cells/plate) and treated as 
described above with GEM and prodrugs of GEM.  After 48 hours, cells were 
collected, washed in 1X PBS, and resuspended in RIPA buffer, pH 8.0 (150 mM 
NaCl, pH 8.0; 50mM Tris-HCl; 1% Igepal; 0.5% Na-Doc; and 0.1% SDS), 1mM 
PMSF, 1mM Na3VO4, 1mM NaF, 2.5mM EDTA, and 1X protease inhibitor 
cocktail (Calbiochem; Merck Millipore) for 30 min on ice. The lysate was 
centrifuged at 2,300 × g for 10 min at 4°C and the supernatant was used for 
proteins quantification. Protein concentration was measured with the Bradford 
Protein Assay Reagent (Thermo Fisher Scientific) using bovine serum albumin as 
a standard. Thirty micrograms of protein extracts were electrophoresed through a 
12% SDS-polyacrylamide gel and electroblotted onto PVDF membranes (Merck 
Millipore). Membranes were then incubated for 1 h at room temperature with 
blocking solution, i.e., 5% low-fat milk in TBST (100 mM Tris, pH 7.5, 0.9% 
NaCl, and 0.1% Tween-20), and incubated overnight at 4°C with the polyclonal 
rabbit clived-PARP primary antibody (1:1000 in blocking solution, Cell 
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signaling). Horseradish peroxidase conjugated polyclonal IgG (1:2000 in blocking 
solution, Cell signaling) was used as secondary antibody. Immunodetection was 
carried out using chemiluminescent HRP substrates (Merck Millipore) and 
recorded with Amersham Hyperfilm ECL (GE Healthcare). To quantify clived-
PARP expression, bands were scanned as digital peaks and the areas of the peaks 
were calculated in arbitrary units using the public domain NIH Image software 
(http://rsb.info.nih.gov/nihimage/), and normalized on alpha-tubulin signal used as 
control. 
5.5 Cell cycle analysis 
Cell cycle distribution was analyzed using propidium iodide (PI)-stained cells. 
Briefly, 5× 105 cells were plated in 60 mm culture plates and treated as described 
above with GEM and prodrugs of GEM. After 48 hours, cells were washed with 
PBS, were collected, and incubated with 0.1% sodium citrate dihydrate, 0.1% 
Triton X-100, 200 µg/ml RNase A and 50 µg/ml propidium iodide (Roche 
Molecular Biochemicals). The analysis was performed through flow cytometry 
(BD FACSCanto, BD Biosciences). Approximately 10,000 gated events were 
acquired for each sample and analyzed using FlowJo software (TreeStar, Inc.). 
Dead cells and debris were excluded based upon forward scatter and side scatter 
measurements. 
5.6 Labeling of autophagic vacuoles with MDC 
To quantify the induction of autophagic process, 5× 105 cells were plated in 60 
mm culture plates and treated as described above with GEM and prodrugs of 
GEM. Following the treatment, cells were incubated with 50 µM of 
monodansylcadaverine (MDC) (Sigma aldrich, Milan) in PBS at 37°C for 15 
minutes. After incubation, cells were washed with PBS, trypsinized and analyzed 
by flow cytometry (BD FACSCanto, BD Biosciences). Approximately 10,000 
gated events were acquired for each sample and analyzed using FlowJo software 
(TreeStar, Inc.). Dead cells and debris were excluded based upon forward scatter 
and side scatter measurements. 
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5.7 Annexin V and Apoptosis Inducing Factor analysis  
 
Cells were seeded in a 24-well plate on glass cover-slips at a density of 
4 × 104/well. After 24 h, cells were treated with 50µM of GEM, C12GEM or 
C18GEM for 48 hours. Cells were then rinsed in PBS and fixed in 4% (w/v) 
paraformaldehyde. After blocking in 5% bovine serum albumin (BSA) and 0,05% 
of triton-X-100, cells were incubated with Annexin V (Molecular probes) 1:40 or 
apoptosis inducing factor (AIF) antibody (Bethyl Laboratories) 1:100 overnight. 
Alexa Fluor conjugated antibodies (Life Technologies) were used as secondary 
antibodies and nuclei were stained with Dapi. Cover-slips were mounted over 
slides in AF1 medium (Dako). Cell images were captured using a confocal laser-
scanning fluorescence microscope Leica SP5 (Leica Microsystem, Manheim, 
Germany) at 63× magnification and analysed using Image J software. For figure 
preparation images were processed using Adobe Photoshop. 
 
5.8 Cytotoxicity assay on primary human pancreatic cancer cells  
 
PDXs- derived tumours (A6L, 12556) and circulating tumour cells (CTC)- 
derived cultures (C75, C76, C102) cells were plated in 96	well cell culture plates. 
Viable cells were counted by Trypan Blue dye exclusion and 3x103 cells were 
seeded in each well and cultured as spheres with DMEM: F12 (Invitrogen, 
Karlsruhe, Germany) supplemented with B27 (GIBCO, Karlsruhe, Germany) and 
bFGF (PeproTech EC, London, UK) in anchorage independent conditions for 3 
days (First generation spheres). First generation tumor spheres were harvested 
using a 40 µm cell strainer, dissociated into single cells by trypsinization, and then 
re-cultured for additional 7 days (second generation spheres). After 3 days, 
spheres were treated with 0.1 µM of DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG or 
LipoCu(DDC)2-2%PEG-3%HA 17000 for 24 hours. Cell viability was evaluated 
using Resazurin Cell Viability Assay Kit as described in section 3.3. Three 
independent experiments were performed for each condition and cell viability was 
reported as the percentage relative to control.    
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5.9 Sphere formation assay  
 
Pancreatic cancer spheres of first and second generation were obtained by 
culturing primary pancreatic cancer cells as described in section 3.8. Ten thousand 
cells were seeded in each well in 24-well cell culture plate and incubated for 3 
days. Then, first and second generation spheres were treated with 0.1 µM of DSF, 
Cu(DDC)2, LipoCu(DDC)2-5%PEG or LipoCu(DDC)2-2%PEG-3%HA 17000 for 
4 days. After treatment, a CASY Cell Counter (Roche Applied Sciences, 
Mannheim, Germany) was used to quantify spheres > 40 microns. Each condition 
was performed in triplicate.  
 
5.10 Statistical analysis  
 
ANOVA (post hoc Bonferroni) analysis was performed by GraphPad Prism 5 
(GraphPad Software) and used for multiple-group comparison. Student's t-test was 
used for individual group comparison. P-values < 0.05, 0.01, 0.001 were indicated 
as *, **, ***, respectively 
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RESULTS 
6. Identification of CSC specific therapy with lipophilic pro-drug 
based strategy 
 
6.1 Chemo-sensitivity of Panc1 CSCs to GEM and lipophilic pro-drug 
treatments 
It is known that CSCs represent a sub-population of quiescent cells within the 
tumor that can sustain its malignant behavior giving rise to more differentiated 
cancer cells and contributing to relapse. However, their high resistance to 
traditional chemotherapy and radiotherapy imposes the development of alternative 
CSCs-targeted therapeutic approaches. Panc1 and Panc1 CSCs were plated in 
96-well cell culture plates. After 24 hours, cells were treated with 50µM GEM and 
the lipophilic pro-drugs C12 GEM and C18 GEM. Cell viability was measured 
with Resazurin Assay after 72 hours (Fig. 14).  
 
 
Fig.14: Comparison of GEM, C12 GEM or C18 GEM antiproliferative activity on Panc1 
and Panc1 CSCs after 72 hours of treatment; values are the mean (±SD) of four 
independent experiments, p value <0.05 is considered significant. 
 
The in vivo antitumor activity of the lipophilic produgs against a variety of 
tumours is generally superior to that of the native drug (175, 176). 
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We observed that the lipophilic pro-drugs were more efficacious than GEM in 
both cell lines, but only Panc1 CSCs showed a high sensitivity to C18 GEM 
treatment with a strong reduction of cell growth.  
This result indicates that C18 GEM is more effective than C12 GEM and GEM 
alone on Panc1 CSCs and then, it could be a potential candidate for a specific 
CSC-targeted therapy.  
 
6.2 Intracellular uptake mechanisms of GEM and lipophilic pro-drugs in 
Panc1 parental cell line and Panc1 CSCs  
 
To explain the greater sensitivity of Panc1 CSCs to C18 GEM treatment than 
parental cell line, we investigated the mechanism of intracellular transport of the 
drugs using different membrane entry inhibitors. In the literature, a wide range of 
nucleoside-derived antitumour drugs, such as gemcitabine, are described to enter 
into the cells through the membrane nucleoside transporters (177). However, for 
the lipophilic prodrugs of GEM, the mechanism of intracellular transport is not 
completely clear. 
Panc1 and Panc1 CSCs were treated with 50µM of GEM, C12 GEM and C18 
GEM plus increasing amounts of the following membrane entry inhibitors: 
methyl-β-cyclodextrin (MβCD), an inhibitor of lipid raft formation by cholesterol 
depletion; chlorpromazine (CPM), an inhibitor of clathrin- mediated uptake; 
dipyridamole, a non-specific inhibitor of membrane nucleoside transporters and 
sulfo-N-succinimidyl oleate (SSO), an irreversible inhibitor of the fatty acids 
translocase CD36. Cell viability was measured with Resazurin assay after 72 
hours of treatment and the condition with each inhibitor alone was tested to 
exclude their toxicity. We found that in Panc1 (fig. 15 A), but not in Panc1 CSCs 
(fig. 15 B), the lipophilic formulations of GEM and GEM alone were dependent 
on nucleoside transporters for entering into the cells, as suggested by the increase 
of cell viability after combined treatment with drugs and dipyridamole.  
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Fig. 15: Effect of the nucleoside transporter inhibitor dipyridamole on the 
antiproliferative activity of GEM, C12 GEM and C18 GEM in Panc1 cells (A) and Panc1 
CSCs (B). Values are the means (±SD) of three independent experiments; p value <0.05 
is considered significant. 
 
 46 
Afterward, we investigated the transport mechanism mediated by CD36, the 
translocase involved in the fatty acids uptake. As shown in fig. 16, in Panc1 
parental cell line (A) and Panc1 CSCs (B), only C18 GEM was in part dependent 
on CD36 for entering into the cells. Indeed, the SSO inhibitor didn’t influence the 
effect of GEM or C12GEM on cell growth and determined its partial rescue only 
after C18 GEM treatment. 
 
 
Fig. 16: Effect of the CD36 inhibitor SSO on the antiproliferative activity of GEM, C12 
GEM and C18 GEM in Panc1 cells (A) and Panc1 CSCs (B). Values are the means (±SD) 
of three independent experiments; p value <0.05 is considered significant.  
 
6.2.1 Investigation of clathrin and lipid rafts-mediated endocytosis 
In contrast to these results, the investigation of the role of clathrin and lipid rafts-
mediated endocytosis, has shown that in both Panc1 parental cell line and Panc1 
CSCs, the inhibitory activity of CPM (fig. 17 A and 17 B) and MβCD (fig. 18 A 
and 18 B) didn’t influence the effect of all the drugs on cell growth, suggesting 
that the lipophilic formulations and GEM alone were not dependent on clathrin 
and on lipid rafts for entering into the cells. 
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Fig. 17: Effect of the clathrin-mediated endocytosis inhibitor chlorpromazine (CPM) on 
the antiproliferative activity of GEM, C12 GEM and C18 GEM in Panc1 cells (A) and 
Panc1 CSCs (B). Values are the means (±SD) of two independent experiments. 
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Fig. 18: Effect of the lipid raft-mediated endocytosis inhibitor methyl-β-cyclodextrin 
(MβCD) on the antiproliferative activity of GEM, C12 GEM and C18 GEM in Panc1 
cells (A) and Panc1 CSCs (B). Values are the means (±SD) of three independent 
experiments. 
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Taken together the data described above suggest that the transport mechanisms of 
the drugs into the cells are different between Panc1 parental cell line and Panc1 
CSCs. This difference suggests that CSCs possess different membrane 
characteristics that affect the entry of the drugs and thus their anticancer activity. 
In Panc1, the uptake of GEM and both lipophilic pro-drugs is strongly dependent 
on membrane nucleoside transporters and partially on CD36 translocase only for 
C18 GEM. On the contrary, in Panc1 CSCs the uptake of C18 GEM is at least 
partially dependent on CD36 translocase and, together with GEM and C12 GEM, 
based on other mechanisms that need further clarification. 
 
6.3 Evaluation of cell inhibition mechanisms by GEM and lipophilic pro-
drugs in Panc1 parental cell line and Panc1 CSCs  
 
6.3.1 Cell cycle is not affected by GEM and lipophilic formulations treatment 
 
To investigate the possible effects of GEM, C12 GEM and C18 GEM treatment 
on the cell cycle, we analyzed the G1-S-G2 phase distribution in the cell 
population by propidium iodide staining. Panc1 and Panc1 CSCs were treated 
with 50 µM of GEM and lipophilic formulations and were analyzed by flow 
cytometry. We observed that the treatment for 48 hours with all drugs didn’t 
affect the cell cycle in either Panc1 (fig. 19 A) or Panc1 CSCs (fig. 19 B). 
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Fig. 19: Effect of GEM, C12 GEM and C18 GEM on cell cycle performed by flow 
cytometry in Panc1 cells (A) and Panc1 CSCs (B). Values are the mean of three 
independent experiments.  
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6.3.2 Analysis of different mechanisms of apoptosis in Panc1 and Panc1 CSCs 
 
It is known that the cytotoxic effect of GEM occours through induction of 
programmed cell death, which correlates with Bcl-2 content (178). The apoptotic 
response to treatment was first investigated through Annexin V staining that is 
used for detecting translocated phosphatidylserine, a hallmark of apoptosis.  
Panc1 and Panc1 CSCs  were plated in a 24-well plates or on glass cover-slips and 
treated with 50µM of GEM, C12 GEM and C18 GEM for 48 hours. After 
treatments, cells were incubated with Annexin V as described in Material and 
Methods and images were captured using a confocal laser-scanning fluorescence 
microscope. As shown in fig. 20, the annexin signal was increased with the 
treatments in Panc1 (A) and Panc1 CSCs (B), as indicated by the increase of 
fluorescence intensity, which was strongest in both cell lines after C12 GEM and 
C18 GEM treatment (C). As it can be seen in the histogram summarizing all the 
data (C), the effect was much stronger in the CSCs.  
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Fig. 20: Confocal microscopy images of Panc1 parental (A) and Panc1 CSCs (B) treated 
for 48 hours with GEM, C12 GEM or C18 GEM and incubated with Annexin V antibody 
and Dapi. Cyan channel shows nuclei labeled with Dapi, magenta channel shows the 
positivity to annexin, and the merge represents cellular association of annexin; C) 
Histogram of the fluorescence intensity of Panc1 parental cells and Panc1 CSCs treated 
for 48 hours with GEM, C12 GEM or C18 GEM and incubated with Annexin V antibody. 
Single cells of three random fields were analysed through Leica LAS software. Values 
are the means (±SEM) of ten ROI values reported as a fold change relative to the control. 
Statistical analysis: *CTRL vs treated in Panc1 CSCs; $ CTRL vs treated in Panc1 P. 
 
We next evaluated the molecular mechanism of apoptosis through the analysis of 
cleaved-PARP expression that is increased following the activation of caspase 3 
during apoptosis. Interestingly, we found a different expression of cleaved-PARP 
between Panc1 and Panc1 CSCs (Fig. 21 A and 21 B). In Panc1 cells, we found 
an increase of cleaved-PARP expression depending on treatments, especially for 
C18 GEM, while in Panc1 CSCs, in all conditions, we found a very low 
expression of clived-PARP that was slightly reduced with treatment.  
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A)  
 
 
 
B) 
 
 
Fig. 21: Effect of GEM, C12 GEM and C18 GEM on apoptosis analyzed through 
cleaved-PARP expression. A) Quantitative evaluation of clived-PARP expression levels 
in Panc1 and Panc1 CSCs. The bands of Western blot analysis were scanned as digital 
peaks and the areas of the peaks were calculated in arbitrary units. The value of alpha-
tubulin was used as a normalizing factor. Values are the mean of two independent 
experiments. P< 0.01 (**) CTRL versus treated and C12 GEM versus C18 GEM. B) 
Representative Western blot analysis of cleaved-PARP expression in Panc1 and Panc1 
CSCs treated with GEM, C12 GEM and C18 GEM. Alpha-tubulin was used as control 
loading. 
 
These results suggest a different mechanism of apoptosis in Panc1 and Panc1 
CSCs induced by the drugs that could be caspase-independent in CSCs. To 
confirm this hypothesis, we investigated the involvement in the apoptosis of the 
mitochondrial protein AIF, following its translocation from the mitochondria to 
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the nucleus. There is no evidence in literature that explains this preferential AIF-
mediated pathway for CSCs. 
In Fig. 22, we have reported representative images of  Panc1 (A) and Panc1 CSCs 
(B) treated with 50 µM of GEM, C12 GEM and C18 GEM for 48 hours, and 
incubated with AIF antibody. 
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Fig. 22: Confocal microscopy images of Panc1 parental (A) and Panc1 CSCs (B) treated 
for 48 hours with GEM, C12 GEM or C18 GEM and incubated with AIF antibody and 
Dapi. Cyan channel shows nuclei labeled with Dapi, red channel shows AIF localization. 
Scale bars, 40 µm. 
 
Only in Panc1 CSCs did we found an evident presence of AIF (red spots) in the 
nucleus after treatment, in particular after C18 GEM treatment. Taken together, 
these data demonstrate that the same treatments induced different apoptotic 
mechanisms by involving PARP in Panc1 and AIF in Panc1 CSCs.   
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B 
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6.3.3 Induction of autophagy after C18 GEM treatment  
To evaluate the autophagic response of cells to treatments with GEM and its pro-
drugs, we analyzed the amount of autophagosomes by flow cytometry, labeling 
the cells with monodansylcadaverine (MDC), a specific marker of autophagic 
vacuoles. MDC accumulates in these vacuoles due to a combination of ion 
trapping and specific interactions with membrane lipids. We found that C18 GEM 
induced an increase of monodansylcadaverine uptake and thus an increase of the 
amount of autophagosomes, in both cell lines (Fig. 23 A and 23 B).  
A) 
  
 
Fig 23: Analysis of autophagy performed through monodansylcadaverine (MDC) assay. 
A) Representative FACS histograms of Panc1 P and Panc1 CSCs untreated or treated for 
48 hours with GEM, C12 GEM or C18 GEM and labeled with MDC; B) Histogram of the 
median fluorescence intensity of Panc1 parental cells and Panc1 CSCs treated for 48 
hours with GEM, C12 GEM or C18 GEM and labeled with MDC. Values are the means 
(±SEM) of three independent experiments and are reported as a fold change relative to 
control. Statistical analysis: * CTRL vs treated; $ or # GEM, C12 GEM vs C18 GEM. 
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Taken together, the data described above indicate that C18 GEM may be a 
potential therapeutic strategy for the specific killing of CSCs. All the treatments 
tested induce a PARP-dependent apoptosis in Panc1 cells and a mechanism of 
caspase-independent apoptosis mediated by AIF in Panc1 CSC. Furthermore, C18 
GEM increases the autophagosomes formation as a response of the cells to stress 
induced by drug treatment. Regarding the intracellular uptake mechanisms, the 
entrance of the lipophilic formulations and of GEM is dependent on nucleoside 
transporters in Panc1 cells, while in Panc1 CSCs the mechanism is yet not clear 
and further studies are needed. 
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7. Identification of CSC specific therapy with disulfiram 
formulations 
  
7.1 Cytotoxicity of Disulfiram and conjugates on Panc1 cells and Panc1 CSCs  
DSF acts as antitumoral drug and represents a  possible candidate as anti-CSC 
agent in glioblastoma and breast cancer (179, 180). As widely reported in 
literature, DSF and dithiocarbamate are able to form stable complexes with metals 
such as copper, zinc, gold and iron (181). To evaluate the antitumor activity of 
DSF or Zn(DDC)2, Cu(DDC)2, Fe(DDC)2 on Panc1 parental cell line or the 
derived Panc1 CSCs, both cell lines were treated at dose ranging from 0 to 100 
µM of these compounds. Cell viability was evaluated after 24 and 72 hours (Fig. 
24) of treatment. In both cell lines Cu(DDC)2 was significantly more efficacious 
than DSF, Zn(DDC)2 and Fe(DDC)2, inducing a concentration-dependent 
reduction of cell growth. 
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Fig. 24: Effect of DSF, Zn(DDC)2, Fe(DDC)2, Cu(DDC)2 on Panc1 P (A and C) and 
Panc1 CSCs (B and D) cell growth. Cells were seeded in 96-wells plates and treated after 
24 hours with increasing concentrations of DSF formulations for 24 h (A and B) or 72 h 
(C and D). Cell growth was determined using the Resazurin cell viability assay. Values 
are the means ±SEM of three independent experiments each performed in triplicate. 
Statistical analysis: DSF or Zn(DDC)2 or Fe(DDC)2 versus Cu(DDC)2, * p < 0.05.  
 
Interestingly, after 24 hours Panc1 CSCs were more sensitive than Panc1 cells to 
DSF treatment (Table 2). Treatments of 72 hours with Cu(DDC)2 showed a 
greater inhibition of cell growth resulting in a total mortality even at low drug 
doses both in Panc1 cells and Panc1 CSCs (Fig. 24 C and D), with IC50 values of 
0.68 ± 0.16 and 0.35± 0.03, respectively (Table 2).  
These results demonstrate that Cu(DDC)2 possesses the strongest antitumor 
activity in our cell line models. For this reason and for its well documented 
anticancer activity (182, 183, 184) it was chosen for the encapsulation in 
liposomes.  
 
7.2 Cu(DDC)2 containing liposomes possess a strong anti-proliferative activity 
on Panc1 cells and Panc1 CSCs  
 
To increase the effectiveness and the blood circulation time of DSF and 
Cu(DDC)2, we next evaluated the cytotoxic activity of liposomes containing DSF 
and Cu(DDC)2. These liposomal formulations were prepared in collaboration with 
the University of Turin. It has been demonstrated that the development of 
liposomes as drug delivery system overcomes problems related to the poor 
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solubility of several anticancer agents and shows efficacy in different tumour 
models, such as breast cancer and acute myeloid leukemia (185, 186). In a control 
experiment, cell viability was shown not to be altered by the presence of 
liposomes alone without drugs (data not shown). The liposomal formulation 
containing DSF (LipoDSF-5%PEG) was significantly more active than free DSF, 
only after 72 hours of treatment, as shown in the IC50 values in Table 2 and in cell 
growth fig. 25, in both cell lines. Moreover, Panc1 CSCs were more sensitive than 
Panc1 to LipoDSF-5%PEG treatment at both incubation times (table 2).  
 
 
Fig. 25: Effect of DSF and LipoDSF-5%PEG on Panc1 P and Panc1 CSCs cell growth. 
Cells were seeded in 96-wells plates and treated after 24 hours with increasing 
concentrations of the drugs for 24h (A) or 72h (B). Statistical analysis: DSF versus 
LipoDSF-5%PEG on Panc1 P or on Panc1 CSC * p < 0.05.  
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Loading of Cu(DDC)2 into the liposomes strongly increased the anti-proliferative 
effect of Cu(DDC)2, making it a potent compound with an excellent antitumour 
activity. 
As shown in Fig. 26, LipoCu(DDC)2-5%PEG demonstrated a higher anti-
proliferative activity than Cu(DDC)2 in Panc1 and Panc1 CSCs, resulting in a 
concentration dose-dependent reduction of cell growth and lower IC50 values 
(Table 2).  
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Fig. 26: Effect of Cu(DDC)2 and of liposome formulations LipoCu(DDC)2-5%PEG, Lipo 
Cu(DDC)2-5%HA 4800, LipoCu(DDC)2-5%HA 17000, LipoCu(DDC)2-2%PEG-3%HA 
4800, LipoCu(DDC)2-2%PEG-3%HA 17000 on Panc1 P (A and C) and Panc1 CSCs (B 
and D) cell growth. Cells were seeded in 96-well plates and treated after 24 hours with 
increasing concentrations of Cu(DDC)2 formulations for 24 h (A and B) or 72 h (C and 
D). Cell growth was determined using the Resazurin cell viability assay. Values are the 
means ±SEM of three independent experiments each performed in triplicate. Statistical 
analysis: liposome formulations versus Cu(DDC)2, * p < 0.05. 
 
To investigate the impact of hyaluronic acid (HA)-coating on the targeting 
capacity to CD44-expressing tumour cells, we next evaluated the anti-proliferative 
effect of Cu(DDC)2 loaded in liposomes coated with HA at two different 
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molecular weights, 4800 and 17000 Da, and/or with different percentage of PEG. 
Liposomal formulations containing either PEG or HA determined a similar 
inhibition of cell proliferation, whereas the presence of both PEG and HA further 
increased the anti-proliferative activity of Cu(DDC)2 at 24 h (Fig. 26 and Table 2), 
in both cell lines. Furthermore, after 72 hours of treatment, Panc1 CSCs were 
more sensitive to liposome formulations with HA17000 and/or PEG compared to 
Panc1 cells (Table 2). 
 
 
Table 2: IC50 values (expressed as µM) on Panc1 P and Panc1 CSC at 24h and 72h after 
the indicated treatments as determined by Resazurin assay, mean ± SEM. P-values < 0.05 
were indicated as $ DSF or Zn(DDC)2 vs Cu(DDC) ; # DSF and DSF conjugates vs 
liposomal complex; £ LipoCu(DDC)2-5%PEG vs LipoCu(DDC)2-2%PEG-3%HA17000 
* P vs CSC. 
 
 
 
 
 
 
IC50  24h (µM) IC50  72h (µM) 
 P CSCs P CSCs 
DSF 85.5±6.0 60.8±5.9* 65.3±4.2 61.0± 10.5 
Zn(DDC)2 86.6±2.4 70.3±10.6 45.2±1.2 41.5±7.6 
Cu(DDC)2 43.6±10.8$ 27.4±7.0$ 0.68±0.16$ 0.35±0.03$ 
LipoDSF 
-5%PEG 73.8±4.2 44.4±0.1* 33.1±0.8# 10.3±1.9#* 
LipoCu(DDC)2-5%PEG 0.46±0.02# 0.68±0.16# 0.28±0.03# 0.08±0.006#* 
LipoCu(DDC)2-
5%HA4800 0.48±0.001# 0.80±0.31# 0.18±0.003# 0.11±0.08# 
LipoCu(DDC)2-
5%HA17000 0.34±0.09# 0.97±0.44# 0.18±0.006# 0.04±0.001#* 
LipoCu(DDC)2-
2%PEG3%HA4800 0.20±0.09# 0.38±0.11# 0.08±0.004# 0.06±0.01# 
LipoCu(DDC)2-
2%PEG3%HA17000 0.14±0.05#£ 0.03±0.004#£ 0.20±0.01# 0.02±0.004#* 
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Interestingly, examining the anti-proliferative effect at a concentration as low as 
0.1 µM, Panc1 CSCs were highly sensitive to liposomal formulations, while 
Panc1 cells were completely resistant (Fig. 27).  
 
 
 
Fig. 27: Effect of DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG and LipoCu(DDC)2-2%PEG-
3%HA 17000 on Panc1 P and Panc1 CSCs cell growth. Cells were treated with 0.1 µM of 
drugs for 24h (A) or 72h (B). Statistical analysis: CTRL versus treated, or as indicated in 
figure * p < 0.05, ** p < 0.01, *** p < 0.001.  
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These results demonstrate that liposomes coated with 2%PEG and 3% HA17000 
are the most effective tested compound on Panc1 CSCs, suggesting an innovative 
formulation that could be used in a CSC- targeted therapy in PDAC. Furthermore, 
these results suggest that liposomes increase the effectiveness of the drugs and 
could prevent their degradation, allowing a cytotoxic prolonged activity over time. 
 
7.3 Cytotoxicity of DSF and Cu(DDC)2 containing liposomes on cells derived 
from PDAC patients 
 
To evaluate the anti-proliferative activity of DSF, Cu(DDC)2, LipoCu(DDC)2-
5%PEG or lipoCu(DDC)2-2%PEG-3% HA17000 on pancreatic cancer cells 
obtained directly from patients, the primary cells 12556, A6L, C75, C76 and C102 
were cultured as spheres, as described in materials and methods, and treated with 
0.1 µM of the formulations mentioned above. Cell viability was evaluated after 24 
h of treatment. In fig. 28, we show that the liposome formulations containing 
Cu(DDC)2 were more effective than free drugs on first generation spheres and 
even more on second generation spheres. These data are particularly interesting 
since they confirm the strong anti-proliferative effect of Cu(DDC)2 containing 
liposomes, obtained with Panc1 cell lines, on cells derived from PDAC patients 
having stem like features. 
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Fig. 28: Effect of DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG and LipoCu(DDC)2-2%PEG-
3%HA 17000 on cell growth of PDAC PDX-derived culture cells (12556, A6L) and 
CTC-derived cells (C75, C76, C102) cultured as first and second generation spheres. 
Cells were treated with 0.1µM of drugs for 24h. Cell growth was determined using the 
Resazurin cell viability assay. Values are the means ±SEM of three independent 
experiments each performed in triplicate. Statistical analysis: CTRL versus treated, or as 
indicated in figure * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Since the copper-drug complexes have not been approved for the use in patients 
because of their extremely low solubility, it is difficult to establish their utility in 
preclinical models or patients. For this reason, the liposome formulations are a 
good strategy to make the Cu(DDC)2 complexes suitable for intravenous 
administration. Moreover, we demonstrate the initial evidence that the liposome 
formulations seem to have a promising potential as CSC-targeting agents.   
 
7.4 Effect of DSF and Cu(DDC)2 containing liposomes on sphere formation 
capability 
 
In the context of CSC features, the sphere formation capability is regularly studied 
in vitro and used to identify new ways for targeting CSCs. We used a specific 
method for culturing primary human pancreatic cancer cells isolated from tissues 
resected during surgery as tumour spheres of first or second generation. In fig. 29, 
we reported the effect of DSF, Cu(DDC)2, LipoCu(DDC)2-5%PEG and 
LipoCu(DDC)2-2%PEG-3%HA17000 on the in vitro sphere formation capability. 
We found that liposome formulations at 0.1µM decreased the number of first 
generation spheres formed, while DSF and Cu(DDC)2 treatment affected slightly 
or didn't affect the sphere number.  
The first generation spheres were subsequently passaged into second generation 
spheres and also the formation of these spheres was drastically reduced after the 
treatment with the liposome formulations. 
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Fig. 29: Effect of DSF, Cu(DDC)2, LipoCu(DDC)2-5% PEG and LipoCu(DDC)2-2% 
PEG-3%HA17000 on 12556, C75, C76, and C102 spheres formation capability. Cells 
were seeded in 24-well plates for first or second generation spheres and treated after 3 
days with 0.1µM of drugs for 4 days. Spheres number was determined through sphere 
formation assay performed by CASY Counter and reported as spheres of 40-80 µm , 80-
120µm and  >120 of diameter. Statistical analysis: CTRL versus treated, or as indicated in 
figure * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Also the cellular morphology was affected by liposome formulation treatment 
(Fig. 30) and the spheres lost their typical shape becoming similar to small cell 
aggregates.  
 
 
 
Fig. 30: Representative images of PDAC spheres. Cells were seeded in 24-well plates and 
treated after 3 days with 0.1µM of drugs for 4 days. The pictures have been acquired at 
day 7 with a 10X objectives. Scale bars, 50µm 
 
Thus, our data demonstrate a significant effect of liposome formulations on the 
self-renewal capacity of primary pancreatic cancer stem like cells. 
 
 
 
 
CTRL DSF Cu(DDC)2 
LipoCu(DDC)2-5%PEG LipoCu(DDC)2-2%PEG-3% HA 17000 
 72 
8. DISCUSSION AND CONCLUSION 
In the last years, cancer stem cell biology represents one of the most controversial 
fields of modern molecular oncology. Since CSC hypothesis has been confirmed 
for leukemia in 1994 (187), other evidence has also emerged for solid tumours, 
including PDAC, indicating that also these tumours are sustained and promoted 
by cells with features of stem cells and self-renewal capacity (188). CSCs have 
several advantages over the differentiated cancer cell population, including high 
resistance to radio- and chemotherapy. For this reason, researches on the 
development of alternative CSCs-targeted therapeutic approaches are of great 
importance. Several studies are providing increasing evidence that direct targeting 
of pancreatic CSCs in combination with the elimination of the more differentiated 
cancer cells increases the efficacy of the treatment, as indicated by a longer 
survival in preclinical xenograft models (189). These studies were focused on the 
inhibition of the most important regulatory pathways that are relevant for the self-
renew ability of CSCs, and on the capability of immune-based treatments to target 
pancreatic CSCs. Moreover, since acquired resistance to treatment is due to 
genetic and epigenetic alterations, specific drugs for the epigenetic regulatory 
machinery have been considered (190, 191). Thus, many therapeutic strategies 
have been designed to specifically target CSCs, but with limited success (192). 
Currently, nanoparticle formulations have been designed to effectively destroy 
these cells or chemical modification of drugs has been devised to improve their 
stability and solubility (193, 194). Nanoparticles can sequester chemotherapeutic 
agents at high concentrations and release them within the cancer cells, achieving 
high cell selectivity by targeting agents on the surface of nanoparticles.  It has 
been demonstrated that this approach provides encouraging results in the 
inhibition of multiple types of CSCs by targeting specific markers (CD44, ALDH, 
CD133) or specific signaling pathways (Notch, Hedgehog and others) (195). 
Furthermore, nanoparticles have been developed to overcome the resistance of 
cancer cells to chemotherapy (196). Reddy et al., reported that a nanoparticle 
formulation of GEM, the 4-(N)-tris-nor-squalenoyl-GEM was more cytotoxic than 
GEM in human and murine leukemia cell lines (197).  
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In this work, we have developed two different therapeutic strategies for the 
treatment of PDAC and for CSC specific killing: 
1. A pro-drug approach that involves the use of GEM conjugated with the 
fatty acid chains, C12 GEM and C18 GEM, for improving GEM stability; 
2. A targeted drug delivery system that involves the development of 
PEGylated liposomes containing DSF or Cu(DDC)2 and liposomes 
selective for pancreatic CSCs, using HA as targeting agent. 
It has been demonstrated that GEM is rapidly deaminated in blood, liver, kidney 
and other tissues, showing a very short half-life (198). Different approaches have 
been tried to improve the GEM metabolic stability and its “in vivo” cytotoxic 
activity, such as the synthesis of an acyl moiety that protects the drug from rapid 
inactivation and improves its antitumour activity compared to the pure drug (199). 
Recently, the antitumor activity of GEM 4-(N)-acyl derivatives (C12 GEM and 
C18 GEM) and their loading into nanoparticles have been studied. Malfanti et al. 
demonstrated that C12 GEM was more toxic than GEM in human ovarian 
carcinoma cells and the prodrug cytotoxicity was reduced after encapsulation into 
nanoparticles (200). The C18 GEM activity was studied in vivo on human 
colorectal adenocarcinoma (HT-29) and nasopharyngeal carcinoma (KB 396p) 
cells (201). The animals treated with C18 GEM had a smaller tumour mass and 
higher percentage of regression than mice treated with GEM alone. Exploring 
the lipophilic pro-drug strategy, we demonstrated that Panc1 CSCs were more 
sensitive to C18 GEM compared to standard treatment with GEM or C12 GEM, 
and respect to Panc1 parental cell line. Furthermore, the two cell lines exhibited 
different intracellular uptake mechanisms of the drugs. In Panc1 parental cell line 
in contrast with CSCs derived cells, the lipophilic formulations and GEM alone 
were dependent on nucleoside transporters for entering into the cells. 
Furthermore, in both cell lines C18 GEM was also dependent on fatty acid 
translocase CD36 for entering into the cells, while in Panc1 CSCs GEM and C12 
GEM crossed the membrane by a mechanism that should still be identified. The 
inhibition data of membrane transporters suggest a different membrane 
composition between Panc1 and CSCs that influences the uptake of drugs and 
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then their antitumor activity. Finally, we characterized the cell growth inhibition 
mechanisms, highlighting another peculiar feature of CSCs regarding the 
apoptotic response to treatment. In Panc1 parental cells, drug treatments induced a 
PARP-dependent apoptosis, while in Panc1 CSCs they activated a mechanism of 
caspase-independent apoptosis mediated by AIF. Furthermore, we demonstrated 
that C18 GEM increased the autophagosomes formation as a response of the cells 
to stress induced by drug treatment. These data highlight the possible use of pro-
drugs of GEM as a therapeutic strategy in the treatment of PDAC, because of their 
high efficiency in killing CSCs with the final aim to permanently remove the 
tumor and prevent recurrence.  
The second therapeutic approach described in this work has demonstrated an even 
greater efficacy towards CSC containing PDAC and is based on the use of 
PEGylated liposome formulations coated with HA and containing the potent 
antiproliferative Cu(DDC)2 complex. The anti-alcoholism drug DSF is a Cu 
ionophore and has been shown to act as antitumoral drug by inducing oxidative 
stress, especially when complexed with Cu (202). It has been demonstrated that 
the cytotoxic activity of DSF, after its degradation to DDC, against U87 and U251 
glioblastoma cells, A549 lung cancer line and  MDA-231BR breast cancer cells is 
copper dependent (203). Despite its potent anticancer activity, the use of DSF-
based cancer therapy in clinic is hampered by its instability in gastric juice and 
bloodstream, and poor solubility in biological fluid. To overcome these 
limitations, the encapsulation of DSF in liposomes is crucial to protect it from 
degradation and renders it suitable for intravenous administration (204). 
Furthermore, the development of liposomes capable of specifically recognizing 
the target cells, strongly increases the therapeutic efficacy of the drug (205). 
Wehbe et al. have resolved, for the first time, the issue related to the high 
insolubility of the diethyldithiocarbamate-copper complexes by synthesizing them 
inside liposomes (203). These liposomal formulations have been characterized 
and the rate of Cu(DDC)2 formation inside the liposome has been quantified, 
resulting directly related to the amount of encapsulated copper. The liposomes 
containing DDC and copper have proved to be  highly cytotoxic against breast 
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cancer stem cells in vitro and in vivo, giving rise to ROS activation and inhibition 
of NFκB pathway (206). 
 In this work, DSF-metal complexes were prepared in collaboration with the 
University of Turin and their anti-proliferative activity was tested on pancreatic 
cancer cells. Among these complexes, the most effective on our cell models, 
Cu(DDC)2, was chosen for the encapsulation in PEGylated formulations or in 
liposomes with HA at two different MW (HA4800 and HA17000). In a previous 
work, it has been demonstrated that liposomes decorated with HA show a strong 
affinity towards pancreatic tumour cells overexpressing CD44 on their plasma 
membrane (207). The anti-proliferative activity of liposomes was evaluated using 
pancreatic CSCs derived from cell lines or patients. Taken together, our results 
demonstrate that the loading of Cu(DDC)2 into the liposomes strongly increases 
the anti-proliferative effect of Cu(DDC)2. Coating with HA generally improves 
the anti-proliferative activity of Cu(DDC)2 containing liposomes only in the 
presence of PEG. Impressive data were obtained using primary cells with a stem 
like phenotype directly derived from PDAC patients in which these formulations 
show a high capacity to inhibit cell proliferation and sphere formation capability. 
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10. ANNEXES 
During the period of my PhD, I have collaborated in a research project focused on 
the study of new therapeutic strategies for the treatment of PDAC. In particular, I 
studied the biological features of cancer stem cells that constitute a distinct 
population of quiescent cells that are resistant to standard therapy and are 
responsible for metastasis and relapses. A part of the project was carried out in the 
Prof. Heeschen’s lab at the Barts Cancer Institute in London, where I spent a 
period of six months.  In this period, I continued to study the effect of new 
therapeuthic strategies on cells directely derived from PDAC patients and cultured 
as tumour spheres having stem like features.  
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Zeeberg K, Cardone RA, Reshkin SJ. - Int J Oncol. 2015 Mar;46(3):1214-
24. doi: 10.3892/ijo.2014.2805. 
2) Secreted molecules inducing epithelial-to-mesenchymal transition in 
cancer development.  
Dalla Pozza E., Forciniti S., Palmieri M., Dando I. Semin Cell Dev Biol. 
2017 Jun 30. pii: S1084-9521(16)30486-4. doi: 10.1016/ 
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3) Extracellular Matrix composition modulates PDAC parenchymal and stem 
cell plasticity and behavior through the secretome.  
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